opening? Another question is whether the coupling of DHPR to RYR1 alters the ability of the DHPR to bind CaM. As mentioned previously, there is a difference in apoCaM modulation of RYR1 and RYR2, in that apoCaM does not appear to modulate the latter. This raises a question as to what differences in primary structure between RYR1 and RYR2 account for differences in activation of the two RYRs by apoCaM.
In summary, it seems likely that CaM binding to the DHPR and RYR must, in some way, modulate E-C coupling in both cardiac and skeletal muscle. Its role may be to regulate the Ca 2+ -dependent enhancement and inhibition of activity or, possibly, to prevent or enhance coupling between the DHPR and RYR1. Since CaM plays a wide variety of roles in both development and cell function, it would be difficult to create a CaM knockout animal model to determine the functional role of CaM in regulation of either cardiac or skeletal muscle E-C coupling. Instead, the most likely approach will be to mutate its binding sites on RYR1 and/or the DHPR, express these mutated channels in cells that are deficient in one of these proteins, and assess the functional consequences. This approach will require the further identification of the molecular determinants on RYR and the DHPR involved in both apoCaM and Ca 2+ CaM binding. If the amino acids needed for apoCaM binding are different from those for Ca 2+ CaM binding, it may be possible to selectively destroy the binding of one form of CaM without greatly altering the interaction of the other form. This would allow the assessment of the functional contributions of the different forms of CaM. 2. Fruen BR, Bardy JM, and Louis CF. Calmodulin activation of skeletal muscle (but not cardiac) ryanodine receptors: modulation by effectors of calcium-induced calcium release (Abstract role in the CNS. In addition to GABAergic nerve fibers, the mucosa of the rodent and human gut contains GABA in endocrine-like cells in the gastric antrum through to the distal colon. This neural and endocrine cell localization for GABA in the gut wall is a feature of other enteric transmitters, including 5-hydroxytryptamine (5-HT), enkephalin, vasoactive intestinal peptide (VIP), somatostatin, and substance P.
There are a number of reviews on GABA as a transmitter in enteric nerves that have focused on GABA, its enzymes, and its mechanisms of action in the ENS. The aim of this review is to show the distribution of the GABAergic system within the mammalian gut wall and how this system fits into a model for GABAergic transmission with multiple signaling pathways. In addition, GABAergic interneurons will be shown to be involved in enteric neural circuits controlling spontaneous and reflex motor and secretomotor activity. When viewed in the context of the extensive pharmacological data on GABA actions in the gastrointestinal tract, the major neuronal and minor endocrine distribution of GABA, and the presence of GABA receptor subunits in the mammalian gut wall, GABAergic neurotransmission must be a major component in the control of gastrointestinal function. It will become evident in the following discussion that GABAergic interneurons represent the ideal candidate for the integration of circuits controlling gut motility and secretion.
GABA in the gut
Neural. Like the CNS, the primary synthesis reaction for enteric GABA is catalyzed by L-glutamate decarboxylase using the substrate glutamate (3). Enteric GABA can also be derived from putrescine via the actions of diamine oxidase/aldehyde dehydrogenase. The highest L-glutamate decarboxylase activity in the gut wall is found in the myenteric plexus. Autoradiographic and immunohistochemical (7) studies collectively demonstrate GABAergic neurons with Dogiel type I and type II morphology in myenteric ganglia. GABAergic neurons have also been visualized in cultures of the myenteric plexus by studies showing the high-affinity uptake, localization, and release of GABA (7) . GABAergic nerve fibers are typically varicose and often form a rich arbor around ganglion cells. In the rat, GABAergic neurons account for >5-8% of the total number of myenteric neurons in the large intestine. Examples of the localization and distribution of GABAergic elements in the gastrointestinal tract are shown in Fig. 1 .
GABAergic myenteric interneurons in the human and rat colon fall into three neurochemically distinct, nonoverlapping subpopulations: 1) neurons with somatostatin, which account for ~40% of the GABA population; 2) neurons with enkephalin, which account for ~10 % of the GABA population; and 3) neurons with NADPH diaphorase-related nitric oxide synthase (NOS) activity, which account for ~20% of the GABA population (Fig. 2) . Neither somatostatin-nor enkephalin-positive cells show NOS activity. GABAergic neurons also occur in submucosa ganglia plexi (7) and are characterized as having Dogiel type I or type II morphologies. GABAergic fibers project within paravascular nerve bundles and, in some instances, within perivascular innervation of the submucosa, as well as to the muscularis mucosae and the mucosa. Within the mucosa, GABAergic nerve fibers ramify within the fine nerve plexus underlying the base of the crypts, which serves as the interface for the innervation of the mucosa.
Within the submucosa and mucosa, GABAergic cells were seen to colocalize either somatostatin or NOS, but not both (Fig. 2) . No enkephalin-containing neural elements and only low levels of methionine enkephalin itself occur in the submucosa compared with the muscularis externa. Myenteric GABA neurons colocalizing enkephalin may represent inhibitory innervation of the muscularis, which modulates cholinergicmediated contractions (3). Conversely, somatostatin neurons are found within the myenteric and submucosal plexi; however, no somatostatin-immunoreactive fibers occur in the muscularis, where most if not all axo-axonic interaction occurs. Indeed, somatostatin has no direct myogenic actions; rather, fibers of somatostatin-containing myenteric neurons project caudally within the ganglionated meshworks of the myenteric plexus, and release of somatostatin either depolarizes or hyperpolarizes distinct populations of myenteric neurons.
Endocrine. In addition to the neural localization, GABA is synthesized, stored, and secreted by mucosal endocrine-like cells (see Fig. 1C ) throughout the rat antrum and intestine (2, 9) . The mucosa, therefore, may well be under the influence of GABA released from local neurons (13) as well as GABA secreted from endocrine cells. In the rodent gastric antrum, GABAergic endocrine-like cells resolve into subpopulations of cells colocalizing either gastrin (G cells) or somatostatin (D cells). In the rodent intestine, GABAergic endocrine-like cells display a morphology similar to D-type endocrine cells (9) . GABA released from these cells into the local circulation or interstitial space may act as a classic gastrointestinal hormone or a local paracrine or autocrine factor. Together, this evidence strongly supports the notion that, in addition to the role of GABA within specific reflex motor responses of the gut related to its myenteric neural localization, GABA originating from submucosal nerves as well as mucosal cells is physiologically important in the control of mucosal activity. Direct myenteric GABAergic neural control of mucosal function may also occur (6); however, it is more likely that GABA effects on mucosal function are related to submucosal GABAergic neurons and/or GABAergic endocrine mucosal cells (13) .
Sites of enteric GABA action
GABA exerts both stimulatory and inhibitory influence over enteric neuronal activity, depending on the GABA receptor subtypes activated: stimulation is via GABA A receptors and inhibition is via GABA B receptors. In addition, GABA A receptors are in pathways that target both excitatory and inhibitory motor neurons, and in this way GABA can "The highest L-glutamate decarboxylase activity in the gut wall is found in the myenteric plexus." both positively and negatively influence smooth muscle behavior and secretion. These GABA receptor-related actions appear to be significant, since gut motility can be blocked or reduced by GABA A or GABA B receptor blockade (3) .
Enteric GABA A display a pharmacology analogous to central GABA A receptors (3). Recently, enteric GABA A receptors have been localized to a subpopulation of myenteric and submucosal neurons in the rat intestine (10), consistent with the well-established neurogenic action(s) of GABA on multiple nerve cell types, including enteric motor nerves. In vitro studies show that applied GABA or GABA A receptor agonists stimulate enteric cholinergic excitatory and nonadrenergic, noncholinergic inhibitory motor neurons (3). In support of this notion, electrophysiological studies indicate that, unlike the brain, in which GABA A mediates hyperpolarization of neurons, enteric GABA mediates depolarization of AH/type II and S/type I myenteric neurons (1). The GABA A receptormediated depolarization of AH/type II cells' chloride-dependent, bicuculline-sensitive process resembles the depolarizing action of GABA on dorsal root ganglion cells (3) and presents the researcher with a powerful tool for the study of enteric nerve-nerve interaction.
GABA A receptors
GABA A receptors are heterooligomers composed of the α-, β-, γ-, δ-, and ε-subunit families. The distribution of GABA A receptor subunit mRNAs in adult rat ENS is heterogenous (17) , reflecting a varied physiological/pharmacological profile of GABA-mediated transmission in both regions. The expression of β2-and/or β3-subunits in the rat intestine (10) has been identified with the use of a specific monoclonal antibody. We also confirmed the presence of GABA A receptor subunit (α, β, γ) mRNAs by in situ hybridization in myenteric and submucosal neurons. We have preliminary data (unpublished) to show that these mRNAs are translated into protein; polyclonal antibodies raised against subunit-specific synthetic peptides show marked immunocytochemical staining in subpopulations of rat enteric neurons in primary culture.
Central GABA A receptors are potentiated by benzodiazepine (BZ) treatment. In the gut, barbiturates and BZ also potentiate GABA A -induced responses, indicative of a "central-type" enteric GABA A receptor (3). The expression of α-, β-, and γ-subunit mRNA is the minimum requirement for functional GABA A receptors with a complete range of BZ pharmacology, and their presence in the gut wall indicates that these GABA A receptors are heterogeneous with respect to their subunit composition. Since GABA in the ENS is excitatory and not inhibitory, the subunit expression and hence function of enteric GABA A receptors and their subunit composites may be fundamentally different from classic central GABA A receptors. The data presented above predict that in the gut, BZ type I (α1) and II (α3 and α5) binding sites are present.
GABA B receptors
Enteric GABA B receptors are prejunctional, operating through calcium channels coupled to G proteins. They are sensitive to β-p-chlorophenyl GABA (baclofen), and their pharmacological profile in enteric circuitry indicates an involvement in prejunctional inhibition of cholinergic motor neurons (3). Hence, activation of the myenteric GABA B receptor system, like enteric enkephalin neurons, decreases acetylcholine release from myenteric cholinergic motor neurons, thereby modulating the intensity of enteric smooth muscle contraction generated. In cultured myenteric neurons, GABA also depresses nicotinic transmission (1) and decreases the size of fast excitatory postsynaptic potentials without changing postsynaptic response to neurotransmitters. This action is indicative of some presynaptic/prejunctional effects similar to those of enkephalin in the ENS. A third functional subclass of GABA receptor, GABA C , has recently been described. These are relatively simple ligandgated chloride channels that are neither inhibited by the classic GABA A receptor antagonist bicuculline nor activated by the GABA B receptor agonist baclofen. Nothing is known about GABA C receptors in the gut. It is likely that enteric GABA C receptors will eventually be found, given that two of the components of the CNS GABA system mediate signaling in the gut wall.
GABA in enteric neural circuits
GABA release from enteric GABAergic nerve processes can be elicited by electric stimulation or by substance P (19), cholecystokinin, or neurotensin (16, 18) . In the rat intestine, a neural circuit consisting of GABA-, somatostatin-, and enkephalin-containing interneurons is proposed to be important for the regulation of descending relaxation. In this circuit, distension activated somatostatin neurons in the gut wall and inhibited enkephalin neurons. This leads to disinhibition of interneurons containing GABA A receptors and subsequent activation of VIP-and/or nitric oxide (NO)-containing motor neurons.
GABAergic interneurons may well represent the site of integration for maintaining normal balance between the excitatory and inhibitory neural influences. In addition to stimulating cholinergic motor neurons, GABA, through GABA A receptors, also stimulates the inhibitory motor neurons that release ATP, VIP, and NO. Consistent with the functional evidence for the influence of GABA on motor neurons is the recent immunohistochemical data (10) that showed that almost half of myenteric nerve cell perikarya, including 35% of the NO-synthesizing neurons, contain GABA A receptors (Fig. 3) . NOS is colocalized in a subpopulation of GABAergic neurons in the human colon and rat intestine, suggesting that NO may also be a transmitter of enteric interneurons.
The identification of GABA B receptor-mediated neural circuits has been hampered by the lack of specific GABA B receptor probes. The only study to date on GABA B receptor localization in the gut (15) reveals a distribution of immunolabeling remarkably coincident with the pattern of high-affinity uptake of [ 3 H]GABA by neural and nonneural cells. Nakajima and coworkers (15) also report that GABA B receptor immunoreactivity colocalized with 5-HT immunoreactivity in mucosal cells of the stomach and intestine. These GABA B receptors modulate release of 5-HT from endocrine cells. Moreover, Nakajima and colleagues (15) also showed GABA B immunoreactivity on neuronal cell somata. However, all of the functional studies to date show only a prejunctional action of baclofen. If the labeling of cell somata is specific, then these must be either nonfunctional receptors or receptors that current pharmacological/physiological techniques cannot assess. The cloning of the GABA B receptor (20) will facilitate labeling of cells containing GABA B receptors and will afford considerable progress toward answering these questions. A highly schematic diagram summarizing the extent of GABA innervation of the gut wall is presented in Fig. 4 .
GABA and gut behavior
Motility and secretion. Disruption of the enteric GABAergic system may have widespread consequences on motility and secretion. GABA and its GABA A receptor analogs affect the release of acetylcholine, gastrin, and somatostatin from rat gastric mucosa (5) . GABA receptors also modulate 5-HT release from enterochromaffin cells, histamine release from mast cells, gastric mucous secretion (12), prostaglandins released from interstitial cells (4), and mucosal electrolyte transport (6, 13) . Mast cell-derived mediators such as histamine transduce antigenic signals into alterations in electrolyte transport, and GABA inhibits the allergic response.
Mucosal function. The influence of GABA on epithelial transport processes has been demonstrated in the guinea pig (13) and rat (6) small intestine. In the guinea pig, neural GABA A receptors and hence GABAergic neurons form an important link in the local submucosal circuits regulating epithelial secretion; the rapid-onset first phase of electrolyte transport in response to applied GABA or its analog 3-aminopropanesulfonic acid is dependent on a GABA A receptoractivated pathway to submucosal cholinergic secretomotor neurons. The second phase of the response to GABA involves a GABA A receptor-mediated submucosal neural pathway that stimulates histamine-releasing cells. In the rat, GABA also mediates mucosal electrolyte transport via GABA A receptors; however, this involves myenteric cholinergic neurons (6). This difference is not surprising, since myenteric vs. submucosal control of mucosal water and electrolyte secretion is well known.
The occurrence of GABAergic fibers at the base of the intestinal crypts as well as GABAergic endocrine cells in the epithelium raises the prospect that, in addition to effects on mucosal function, enteric GABA may also influence epithelial cell mitosis and migration. Interestingly, decreased mucosal cell turnover has been shown to be involved in stress-induced gastric ulceration, and this may be a mechanism by which GABA exerts its protective effects in these gut disease models. This warrants further investigation. A model for this can be seen in the liver, in which GABA applied systemically inhibits rat hepatic regenerative activity, whereas GABA A receptor antagonism stimulates regeneration (14) .
Blood flow. In addition to control of motility and secretion, we have preliminary evidence for GABA modulation of mucosal blood flow. GABA or Lioresal (baclofen) produces a dose-dependent reduction in local mucosal blood flow that was not prevented by the GABA A antagonist bicuculline. The effect appeared to be region specific, evident primarily in the rat proximal duodenum with little or no effect in the more distal regions of the duodenum. This effect of GABA is consistent with that observed in the CNS, in which GABA has been shown to inhibit cerebrovascular adrenergic neurotransmission by GABA B receptors. The extent of enteric GABAergic control of local mucosal blood flow needs to be investigated.
Ulceration. Experimental duodenal ulceration in rats is sensitive to systemic treatment with GABA analogs and antagonists. Systemically applied GABA aggravates duodenal ulcers by stimulation of the GABA A receptor, whereas treatment with the GABA B receptor agonist baclofen causes a reduction in both the incidence and intensity of ulcers (8) . Baclofen was found to be more effective than the histamine H 2 blocker cimetidine, and, when given together, the antiulcer actions of these agents were found to be additive. Thus GABA B receptors present an alternative pharmacological site for targeting of antiulcer drug therapies. The mechanism of GABA involvement in duodenal ulcers is unknown. However, since barbiturates and BZs can directly potentiate GABA A receptor-mediated actions in the gut, they could potentiate the aggravating actions of GABA on duodenal ulcers.
Neurogenic interactions between GABA and 5-HT and between GABA and somatostatin have been demonstrated. Thus a GABA-, somatostatin-, and 5-HT-sensitive release of acidic gastric secretions into the duodenum and/or alteration in local blood flow following delayed gastric emptying may be a key element in peptic ulcer disease. This likely represents only some of the interactions of GABA within neural circuits underlying enteric reflex control of the gut wall that may have importance for gut pathophysiology.
Summary
We are beginning to understand in some detail the types of neural innervation and interaction occurring in the mammalian gastrointestinal tract. In this review, the reader is alerted to the presence of a widespread and powerful GABA signaling system in the gut. GABA is involved in the neural and endocrine/paracrine regulation of diverse functions within the gut. GABA can either stimulate (via GABA A receptors) or inhibit (via GABA B receptors) intrinsic cholinergic motor neurons that are responsible for the ascending excitation limb of the peristaltic reflex. Thus disruption of enteric GABA transmission could potentially contribute to the cholinergic hypercontraction of the gut. Intrinsic enteric GABAergic neurons also target (via GABA A receptors) inhibitory gut motor neurons. Enteric GABA A receptor antagonism also stops spontaneous intestinal motility, and this occurs because interference with GABA A transmission damps the circuitry generating intestinal motor activity. This is consistent with the view that, in the ENS, GABA is a transmitter of interneurons within separate excitatory and inhibitory pathways regulating gut motor and secretomotor function. The division of GABAergic interneurons into distinct subpopulations of neuropeptide or NOS-containing cells may reflect the pharmacology of these transmitters with respect to the pattern of transmitter release during reflex control of gut motor and secretomotor function.
The extent of the enteric GABAergic system, together with the disruption in gut behaviors following the perturbation of either the GABA A or the GABA B receptor, suggests that the GABAergic system presents potential new target sites for the development of gastrointestinal drugs. For example, BZs taken orally depress gastrointestinal motility. Diazepam is commonly used for sedation before many gastroenterology procedures as an adjunct to general anesthesia. Therefore, understanding BZ actions in the gut will aid further development of BZ sedatives. The fact that there is a heterogeneous expression (within the enteric nerve layers) of GABA A receptor subunits that define BZ sites will allow us to characterize the physiology and pharmacology of enteric neural BZ sites and their behavior. This will be further aided by the study of synaptic mechanisms related to ganglionic GABA transmission and GABA actions within the enteric neuropil.
For the physiologist, an appreciation of this large yet unheralded enteric nerve-nerve signaling system, which targets cholinergic, peptidergic, purinergic, and NO enteric neurons, affords new opportunities for understanding ENS function in health and disease. Furthermore, the biochemical and pharmacological similarities between the CNS and ENS makes the gut a model system in which to study GABA. Indeed, considering its ease of accessibility, monolayer plexiform anatomic organization and sensitivity to pharmacological, electrophysiological, and molecular analysis, it presents an ideal model system to study GABA, its enzymes, and receptor-related signaling.
